



(51) International Patent Classification:

A61P 25/28 (2006.01) A61K 31/7125 (2006.01)

A61K 31/7088 (2006.01) C12N 15/113 (2010.01)

(21) International Application Number:

PCT/US2021/052580

(22) International Filing Date:

29 September 2021 (29.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/086,495 01 October 2020 (01.10.2020) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, Massachusetts 02142 (US).

(72) Inventors: SOUNDARAPANDIAN, Mangala

Meenakshi; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). DANG, Lan Thi Hoang; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). MCININCH, James D.; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). SCHLEGEL, Mark K.; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). CASTORENO, Adam; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West

Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). KAITTANIS, Charalambos; c/o ALNYLAM PHARMACEUTICALS, INC., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US).

(74) Agent: COWLES, Christopher R.; Withers Bergman LLP, 245 First Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every



kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SNCA RNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES

FIG. 1



(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SNCA gene, as well as methods of inhibiting expression of a SNCA gene and methods of treating subjects having a SNCA-associated neurodegenerative disease or disorder, e.g., Parkinson's Disease (PD), multiple system atrophy, Lewy body dementia (LBD), among other synucleinopathies, using such dsRNAi agents and compositions.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*